Company
Product List
Offer to buy
Offer to sell
Sign In
Join
Help
Languages
English
繁體中文
簡體中文
Changchun Changsheng Life Sciences Ltd.
Home
Company Profile
Products
Video
Inquiry
Contact Us
Recommended Results
Inactivated Flu Vaccine for human
Category :
Chemicals->Chemical->aspalthic products
View Larger Picture
View Larger Picture
View Larger Picture
Product Specification
Model No:
0.5 ml/vial
Country
CN
Brand
WANXIN
Minimum Order
5000
Payment Term
L/C,T/T
Product Detail
<p class="MsoNormal">
<br />
</p>
<p class="MsoNormal" style="text-align:center;">
<b>Influenza Vaccine (Split Virion), Inactivated</b><b></b>
</p>
<p class="MsoNormal">
Influenza Vaccine (Split Virion) is a preparation made from the prevalent strains of influenza virus type A and type B recommended by WHO and approved by the NRA. The strains of influenza virus type A and type B are grown separately in embryonated chicken eggs. After cultivation, the virus suspensions in allantoic cavities are harvested, inactivated, purified,disrupted and repurified to make the vaccine. It is used to prevent the infections of the prevalent strains of influenza viruses.
</p>
<p class="MsoNormal" style="text-indent:24.0000pt;">
Apply the most advanced technology in the world to production of influenza vaccine and arrange vaccine production and quality control according to current influenza virus recommended by WHO. Each quality index of the influenza vaccine is excellent.
</p>
<p class="MsoNormal" style="text-indent:24.0000pt;">
<span>[</span>Eligibles<span>]</span>
</p>
<p class="MsoNormal" style="text-indent:24.0000pt;">
Susceptible individuals and persons liable to be afflicted with the associated complications, such as children, elderly persons and individuals in the epidemic area.
</p>
<p class="MsoNormal" style="text-indent:24.0000pt;">
<span>[</span>Function and use<span>]</span>
</p>
<p class="MsoNormal" style="text-indent:24.0000pt;">
The product can induce immunity against influenza virus in recipients following immunization. It is used to prevent the infections of the prevalent strains of influenza viruses.
</p>
<p class="MsoNormal" style="text-indent:24.0000pt;">
<span>[</span>Specifications<span>]</span>
</p>
<p class="MsoNormal" style="text-indent:24.0000pt;">
0.25 ml or 0.5 ml per container. 0.25 ml per single human dose (used for children aged between 6 months and 3 years) .shall contain 7.5μg of influenza haemagglutinin of each influenza virus strain. 0.5 ml per single human dose (used for adult and children aged above 3 years) shall contain 15μg of influenza haemagglutinin of each influenza virus strain.
</p>
<p class="MsoNormal" style="text-indent:24.0000pt;">
[Contraindications]<br />
(l) Subjects with known allergic reaction to some components of the vaccine, including subsidiary<br />
materials, formaldehyde, chemicals used for virus desruption and antibiotics.<br />
(2) Subjects with acute diseases, severe chronic diseases, and chronic diseases at acute attack stage<br />
or fever.<br />
(3) Pregnant women.<br />
(4) Subjects with uncontrolled epilepsy, other progressive diseases of nervous system or a history of Guillain-Barre syndrome;<br />
[Precautions]<br />
(1) The vaccine shall be administered with caution to the subjects with family or individual history of convulsion and those with chronic diseases, history of epilepsy and allergic diathesis.<br />
(2) Do not use the vaccine if the container shows abnormalities, such as crack, illegible label, exceeding expiry date or turbidity.<br />
(3) The vaccine shall be administered immediately after the container is opened.<br />
(4) Adrenaline should be available for first aid in case of severe anaphylactic reactions. The recipients shall be observed for at least 30 minutes on site following injection.<br />
(5) The immunization with this vaccine should be deferred for at least 3 months following administration of immunoglobulin to avoid the influence on immune effect.<br />
(6) Revaccination should be prohibited if any reactions of nervous system would occur after injection.<br />
(7) Freezing is strictly forbidden.
</p>
<p class="MsoNormal" style="text-indent:24.0000pt;">
[Advantages]
</p>
<p class="MsoNormal" style="margin-left:21.2500pt;text-indent:-21.2500pt;">
(1) Apply centrifugal purification and column chromatography purification technology to purifying virus and obtained the patent certificate of making use of Sepharose4FF column chromatography technology for vaccine manufacture. The product quality index is excellent and the purity is high;
</p>
<p class="MsoNormal" style="margin-left:21.2500pt;text-indent:-21.2500pt;">
(2) Obtained National Ten Famous-brand Products Honor Certificate in pharmaceutical industry;
</p>
<p class="MsoNormal" style="margin-left:21.2500pt;text-indent:-21.2500pt;">
(3) High-level GMT of conversion rate of serum antibody with safety and reliable effect for prevention;
</p>
<p class="MsoNormal" style="margin-left:21.2500pt;text-indent:-21.2500pt;">
(4) Various Specifications<span>:</span>
</p>
<p class="MsoNormal" style="margin-left:21.2500pt;text-indent:-21.2500pt;">
1) Vial type for adult: 0.5ml/vial for people above 3 years old;
</p>
<p class="MsoNormal" style="text-indent:24.0000pt;">
Vial type for children<span>:</span><span>0.25ml/vial for children from 6 to 35 months old;</span>
</p>
<p class="MsoNormal" style="margin-left:21.2500pt;text-indent:-21.2500pt;">
2) Syringe type for adult: 0.5ml/syringe for people above 3 years old;
</p>
<p class="MsoNormal" style="text-indent:24.0000pt;">
Syringe type for children<span>:</span><span>0.25ml/syringe for children from 6 to 35 months old;</span>
</p>
<p class="MsoNormal" style="margin-left:21.2500pt;text-indent:-21.2500pt;">
(5) Exclusively apply two dosage forms of pre-filled syringe from American BD Company and vial pack for security and convenience;
</p>
<p class="MsoNormal" style="margin-left:21.2500pt;text-indent:-21.2500pt;">
(6) Rated as National New and Key Product by the Ministry of Science and Technology, Ministry of Foreign Trade and Economic Cooperation, State General Administration of Supervision, Inspection and Quarantine, State Environmental Protection Administration of China; rated as Excellent Technology Product by China Association for Science and Technology; award the Honor of Science and Technology Progress by Changchun City Administration of Science and Technology;
</p>
<p class="MsoNormal" style="margin-left:21.2500pt;text-indent:-21.2500pt;">
(7) Successfully registered in over 20 countries and export to dozens of countries for consecutive years.
</p>
<p>
<br />
</p>
<p>
<img src="http://i.bosscdn.com/product/4b/7c/6b/3e1521af692db14cd8709065d6.jpg@watermark=2&color=I0ZGRkZGRg%3D%3D&type=ZHJvaWRzYW5zZmFsbGJhY2s%3D&size=22&p=9&t=80&text=Y3MtdmFjY2luZS5ib3NzZ29vLmNvbQ%3D%3D" title="Influenza Vaccine-vial" alt="Influenza Vaccine-vial" />
</p>
<span><br />
</span>
<p>
<br />
</p>
<p class="MsoNormal">
<span><br />
</span>
</p>
<p class="MsoNormal">
<br />
</p>ccls-vaccine.com
More Products from this Supplier
Preventing Chickenpox Immunization Vaccine
Trivalent Influenza vaccine (Split Virion)
Rabies Vaccine(Vero Cell) Injection
Vaccinate Hepatitis A vaccine
[ Back Products Catalog ]
Commerce Member:
Please log in your ID and password, we will later fill in relating info.
ID:
Password:
Remember my ID on this computer
Complete this form below to send out your enquiries.
All enquiries will be automatically sent to the company you want to develop.
Subject
Content
(Don't input Company Name, E-Mail, Phone Number, Fax Number, and URL)
Company Profile:
*
Company Name
*
E-mail
*
Country
Please Select Your Country
United States
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaidjan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Cook Islands
Costa Rica
Croatia
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
East Timor
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
Former Czechoslovakia
Former USSR
France
France (European Territory)
French Guyana
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Great Britain
Greece
Greenland
Grenada
Guadeloupe (French)
Guam (USA)
Guatemala
Guinea
Guinea Bissau
Guyana
Haiti
Heard and McDonald Islands
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique (French)
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldavia
Monaco
Mongolia
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
Neutral Zone
New Caledonia (French)
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Island
Poland
Polynesia (French)
Portugal
Puerto Rico
Qatar
Reunion (French)
Romania
Russian Federation
Rwanda
S. Georgia & S. Sandwich Isls.
Saint Helena
Saint Kitts & Nevis Anguilla
Saint Lucia
Saint Pierre and Miquelon
Saint Tome (Sao Tome) and Principe
Saint Vincent & Grenadines
Samoa
San Marino
Saudi Arabia
Senegal
Seychelles
Sierra Leone
Singapore
Slovak Republic
Slovenia
Solomon Islands
Somalia
South Africa
South Korea
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen Islands
Swaziland
Sweden
Switzerland
Syria
Tajikistan
Taiwan
Tanzania
Thailand
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
Uruguay
Uzbekistan
Vanuatu
Vatican City State
Venezuela
Vietnam
Virgin Islands (British)
Virgin Islands (USA)
Wallis and Futuna Islands
Western Sahara
Yemen
Yugoslavia
Zaire
Zambia
Zimbabwe
*
Contact Person
URL
*
Phone
-
-
Fax
-
-
*
Postal code
*
City
*
Street Address
*
Business Nature
Distributor
Exporter
Importer
Manufacturer
Whole Sale
Retailer
Reseller
Retrofitter
User
Others, please specify:
*
Security Code
Enter the security code.
Site Map l
Privacy Policy l
Company Profile l
Corporate Proposal l
Contact Us l
Help l
Advertise With Us l
World Trade Link
.